Vorasidenib plus PEP-IDH1M vaccine for recurrent IDH1-mutant glioma
Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma
Combining an oral drug called vorasidenib with a vaccine that targets the mutant IDH1 protein aims to help adults with recurrent IDH1-mutant glioma while using MRI-based spectroscopy to watch tumor chemistry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11178424 on NIH RePORTER |
What this research studies
You would take an oral drug called vorasidenib and receive a tumor-specific peptide vaccine (PEP-IDH1M) intended to teach your immune system to recognize the IDH1-mutant tumor. Doctors will use non-invasive magnetic resonance spectroscopy (MRS) alongside standard MRI, blood tests, and clinic visits to track a tumor chemical called 2HG and other signs of response. The hope is that lowering 2HG will reduce immune suppression and let vaccine-primed T cells better attack the tumor. Study visits, imaging, dosing, and safety monitoring would occur at the study site.
Who could benefit from this research
Good fit: Adults with recurrent glioma whose tumor carries the IDH1 mutation and who meet medical and imaging eligibility criteria would be the ideal candidates.
Not a fit: People without an IDH1-mutant tumor or those with rapidly progressive high-grade glioblastoma are unlikely to benefit from this targeted combination.
Why it matters
Potential benefit: If successful, this approach could slow tumor growth, improve symptoms or quality of life, and give doctors a non-invasive way to watch treatment effects.
How similar studies have performed: Vorasidenib and IDH1-targeted peptide vaccines have shown promise separately in early work, but combining them and pairing with MRS monitoring is a more recent and less tested approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Soher, Brian J — Duke University
- Study coordinator: Soher, Brian J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.